trending Market Intelligence /marketintelligence/en/news-insights/trending/uY4zS8gHVHP-3tkLcXxY0g2 content esgSubNav
In This List

Generex Biotechnology to spin out subsidiary into new public company

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Generex Biotechnology to spin out subsidiary into new public company

Generex Biotechnology Corp. plans to spin out its subsidiary, NuGenerex Immuno-Oncology, as a separate publicly traded company.

Miramar, Fla.-based Generex said it would issue one or more dividends of NuGenerex Immuno-Oncology shares to its stockholders under the spinout and intends to retain a controlling interest in the new company.

According to a Jan. 4 press release, Generex will seek to list the new company on a national stock exchange.

Generex expects the spinout, which is subject to market conditions and regulatory requirements, to be completed after the annual meeting of its stockholders.

The biotechnology company is searching for candidates for NuGenerex Immuno-Oncology's board and executive team.